Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
| 06-2019 | 12-2018 | 09-2018 | 06-2018 | 12-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 696,405 | 1,894,169 | 1,154,682 | 593,354 | 1,642,984 |
| Depreciation Amortization | 154,809 | 425,028 | 286,605 | 147,936 | 430,351 |
| Accounts receivable | -200,300 | -239,819 | 51,201 | -117,576 | -179,833 |
| Accounts payable and accrued liabilities | -409,391 | 397,109 | -102,807 | -53,930 | -460,620 |
| Other Working Capital | -737,637 | -315,585 | -384,498 | -372,526 | -683,244 |
| Other Operating Activity | 563,563 | -348,141 | 3,591 | 144,790 | 1,166,888 |
| Operating Cash Flow | $67,449 | $1,812,761 | $1,008,774 | $342,047 | $1,916,526 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -66,539 | 18,815 | 48,888 | 84,824 | -169,153 |
| Net Acquisitions | -46,756 | -171,681 | -12,834 | N/A | -547,946 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -6,212 |
| Sale Of Investment | N/A | N/A | N/A | N/A | 61,935 |
| Purchase Sale Intangibles | -28,720 | -177,519 | -88,713 | -45,807 | -82,485 |
| Other Investing Activity | -13,969 | -100,437 | -106,011 | -62,321 | -173,728 |
| Investing Cash Flow | $-127,264 | $-253,303 | $-69,957 | $22,503 | $-835,105 |
| Cash Flows From Financing Activities | |||||
| Common Stock Repurchased | -9 | -893,916 | -903,951 | -255,631 | -629,337 |
| Dividend Paid | -326,062 | -641,387 | -320,139 | -327,253 | -637,543 |
| Other Financing Activity | -41,150 | -7,423 | -4,176 | 626 | -6,684 |
| Financing Cash Flow | $-367,221 | $-1,542,726 | $-1,228,266 | $-582,259 | $-1,273,563 |
| Exchange Rate Effect | -42,998 | -4,254 | 65,673 | 15,410 | 109,897 |
| Beginning Cash Position | 2,830,773 | 2,952,406 | 2,985,579 | 3,051,925 | 3,034,215 |
| End Cash Position | 2,360,740 | 2,948,534 | 2,761,803 | 2,849,617 | 2,951,979 |
| Net Cash Flow | $-470,033 | $-3,872 | $-223,776 | $-202,308 | $-82,236 |
| Free Cash Flow | |||||
| Operating Cash Flow | 67,449 | 1,812,761 | 1,008,774 | 342,047 | 1,916,526 |
| Capital Expenditure | -66,812 | -129,424 | -82,278 | -46,322 | -172,891 |
| Free Cash Flow | 637 | 1,683,337 | 926,496 | 295,725 | 1,743,635 |